About Glucoset
Glucoset is a Healthcare company based in Trondheim (Norway) founded in 2013, and was acquired by Televenture in April 2015. Continuous intravascular blood glucose monitoring devices are developed. It operates in the Healthcare and Technology sectors. Glucoset has raised $6.59 million across 9 funding rounds from investors including European Union, Norwegian Research Council and EIC Fund. The company has 20 employees. Glucoset offers products and services including GlucoSet Sensor. Its focus areas include Semiconductors, Sensors, Generic Sensor Developers and Biological. Its legal entity is GlucoSet AS.
Company details
Glucoset was founded in 2013 in Trondheim, Norway, and operates in the medical devices sector. Intravascular sensors for continuous blood glucose monitoring are produced, allowing access through existing arterial catheters without additional insertions or equipment displacement. Glucose levels are tracked in real time for patients, supporting level normalization. The sensors are designed for compatibility with patient movement and reduced cross-sectional area relative to alternatives.
- Headquarters Trondheim, Norway
- Employees 20
- Stage Acquired
- SectorsHealthcareTechnology
- Website glucoset.com
- Social LinkedIn
- Acquired by Televenture (Apr 2015)
- Legal Name Glucoset As
- Annual Revenue$104.68 K (USD)374as on Dec 31, 2021
- Net Profit-$601.85 K (USD)-131as on Dec 31, 2022
- EBITDA-$474.9 K (USD)-170as on Dec 31, 2022
- Total Equity Funding$6.59M (USD)
in 9 rounds
- Latest Funding Round$6.52M (USD), Series A
Jul 2023
- InvestorsEuropean Union
& 5 more
- Employee Count20
- Acquired byTeleventure
(Apr 2015)
Products & Services of Glucoset
Glucoset offers a comprehensive portfolio of products and services, including GlucoSet Sensor.
Minimally invasive sensor for continuous blood glucose monitoring in ICU
Funding Insights of Glucoset
Glucoset has successfully raised a total of $6.59M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $6.52 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.59M
- Total Rounds 9
- Last Round Series A — $6.52M
- First Round $52,954
(Jun 2016)
- Investors Count 5
All 9 funding rounds of Glucoset with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $6.52M | Series A | – | Swiss Diabetes Venture Fund | – |
| Jul 2023 | $3.7M | Grant | – | – | |
| Jan 2023 | Series A | – | – | ||
| Nov 2020 | $59,811 | Grant | – | – | |
| Oct 2018 | $2.84M | Grant | – | – | |
| Sep 2018 | $70,000 | Angel Round | – | – | – |
| Mar 2017 | $10,095 | Grant | – | – | |
| Nov 2016 | $53,040 | Grant | – | – | |
| Jun 2016 | $52,954 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Glucoset
Glucoset has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Norwegian Research Council and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Investments are focused on diabetes technology startups worldwide. | diabetesfund.vc | Zürich, Switzerland | ||
Televenture is recognized as a leading venture capital firm in Norway. | 1993 | televenture.no | Oslo, Norway | |
| serpentine.vc | ||||
Research policy advice is provided to the Norwegian government. | 1993 | forskningsradet.no | Oslo, Norway | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Glucoset
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Glucoset
4 dated milestones of Glucoset across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Glucoset is founded.
- Exit Acquired by Televenture.
- Funding First funding round of $53K.
- Funding Latest funding round, Series A, of $6.5M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glucoset
Complete news archive for Glucoset
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glucoset
Glucoset was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Glucoset is headquartered in Trondheim, Norway. It is registered at Trondheim, Trøndelag, Norway.
Glucoset is a funded company, having raised a total of $6.59M across 9 funding rounds to date. The company's 1st funding round was a Grant of $52.95K, raised on Jun 2016.
Glucoset has 20 employees.
Annual revenue of Glucoset is $104.68K as on Dec 31, 2021.
Glucoset was founded in 2013 in Trondheim, Norway, and operates in the medical devices sector. Intravascular sensors for continuous blood glucose monitoring are produced, allowing access through existing arterial catheters without additional insertions or equipment displacement. Glucose levels are tracked in real time for patients, supporting level normalization. The sensors are designed for compatibility with patient movement and reduced cross-sectional area relative to alternatives.
Glucoset offers GlucoSet Sensor.
Glucoset has 6 investors. Key investors include European Union, Norwegian Research Council, EIC Fund, Diabetes Venture Fund, and Televenture.
Glucoset operates through Glucoset As.
Yes. Glucoset was acquired by Televenture in April 2015.